Patents by Inventor Henri S. Lichenstein

Henri S. Lichenstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
    Patent number: 7189693
    Abstract: The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: March 13, 2007
    Assignee: CuraGen Corporation
    Inventors: Michael E. Jeffers, William J. LaRochelle, Henri S. Lichenstein
  • Compositions and methods of use for a fibroblast growth factor
    Publication number: 20040214759
    Abstract: In methods of using a fibroblast growth factor, such as for treating, preventing or delaying a proliferation-associated disorder, steps are provided to administer to a subject a therapeutically effective amount of a particular fibroblast growth factor polypeptide, or variant or fragment thereof.
    Type: Application
    Filed: May 9, 2003
    Publication date: October 28, 2004
    Inventors: John P. Alsobrook, Enrique Alvarez, David W. Anderson, Joel S. Bader, Ferenc L. Boldog, Catherine E. Burgess, Rajeev A. Chillakuru, Lisa Deegler, Shlomit R. Edinger, Elma R. Fernandes, Linda Gorman, William M. Grosse, John L. Herrmann, Michael E. Jeffers, William J. LaRochelle, Denise M. Lepley, Henri S. Lichenstein, Kumar Namdev, Muralidhara Padigaru, Carol E. A. Pena, Sudhirdas K. Prayaga, Daniel K. Rieger, Richard A. Shimkets, Pascal Valax, Meijia Yang, Zachary Yim, Mei Zhong
  • Semaphorin-like proteins and methods of using same
    Publication number: 20040018977
    Abstract: The proteins of the invention are a family used to modulate the activity of cells and their ability to attract blood vessels. The proteins are used to inhibit angiogenesis, inhibit cell migration, and inhibit actin filament formation. These proteins are used in this context to diagnose and treat proliferative disorders such as cancer.
    Type: Application
    Filed: May 30, 2003
    Publication date: January 29, 2004
    Inventors: Enrique Alvarez, David W. Anderson, Mohanraj Dhanabal, Nikolai V. Khramtsov, William J. LaRochelle, Henri S. Lichenstein, Li Li, Chean Eng Ooi, Muralidhara Padigaru, Richard A. Shimkets, Mei Zhong
  • Compositions and methods of use for an ephrin receptor
    Publication number: 20040018199
    Abstract: In methods of using an ephrin receptor, such as for treating, preventing or delaying a proliferation-associated disorder such as cancer, steps are provided to administer to a subject a therapeutically effective amount of an antibody directed to an ephrin receptor polypeptide, variant or fragment thereof.
    Type: Application
    Filed: May 29, 2003
    Publication date: January 29, 2004
    Inventors: Raj Bandaru, Amitabha Chaudhuri, Katherine Fries, Michael E. Jeffers, William J. LaRochelle, Henri S. Lichenstein, Uriel M. Malyankar, Chean Eng Ooi, Sudhirdas K. Prayaga, Raymond J. Taupier
  • Treatment of inflammatory bowel disease using growth factors
    Publication number: 20040006015
    Abstract: The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.
    Type: Application
    Filed: December 16, 2002
    Publication date: January 8, 2004
    Inventors: Ferenc L. Boldog, Catherine E. Burgess, Elma R. Fernandes, Michael E. Jeffers, William J. LaRochelle, Henri S. Lichenstein, Jeffrey Peterson, Sudhirdas K. Prayaga, Beth Rittman, Juliette B. Shimkets, Richard A. Shimkets, Meijia Yang
  • Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
    Publication number: 20030224991
    Abstract: Novel anti-angiogenesis proteins and the nucleic acid sequences which encode them are disclosed by the present invention.
    Type: Application
    Filed: March 11, 2003
    Publication date: December 4, 2003
    Inventors: Mohanraj Dhanabal, Frank Wu, William J. LaRochelle, Henri S. Lichenstein
  • Anti-inflammatory CD14 polypeptides
    Patent number: 5869055
    Abstract: The invention relates to anti-inflammatory polypeptides comprising soluble CD14 related polypeptides having amino acids at position 7-10 that are different from the native sequence or having amino acids 1-14 deleted.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 9, 1999
    Assignee: Amgen, Inc.
    Inventors: Shao-Chieh Juan, Henri S. Lichenstein, Samuel D. Wright
  • Anti-inflammatory CD14 peptides
    Patent number: 5766593
    Abstract: The invention relates to anti-inflammatory peptides that are based on peptide regions 7-10, 11-14, and 57-64 of CD14.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: June 16, 1998
    Assignee: Amgen Inc.
    Inventors: Henri S. Lichenstein, Samuel D. Wright, Linda O. Narhi, Shao-Chieh Juan